Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#1131 M-TORC1 Complex Is Significantly Over-Activated in SDHx-Mutated Paragangliomas

Introduction: The activation patterns of mTOR pathway in sporadic and hereditary pheochromocytomas (PCC) and paragangliomas (PGL) are poorly recognized.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Volante M

Authors: Oudijk L, Papathomas T, De Krijger R, Gimenez-Roqueplo A, Mannelli M,

Keywords: PCC, PGL, mTOR, SDHx,

#946 Immunohistochemical Staining of Catecholamine-Synthesizing Enzymes in Head and Neck Paraganglioma Tissue

Introduction: Head and neck paragangliomas (HNPGLs) are non-producing neuroendocrine tumors, alhough 19-28% of patients have an increased dopamine production. The high sensitivity of 18F-DOPA PET also shows that these tumors might be able to synthesize catecholamines.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Van der Horst-Schrivers A, Osinga T, Korpershoek E, De Krijger R, Kerstens M,

Keywords: paraganglioma, dopamine,

#850 Expression of IGF/mTOR Pathway Components in Human Pheochromocytomas and In Vitro Inhibition of PC12 rat Pheochromocytoma Cell Growth by mTOR Inhibitors alone and in Combination with the Dual IGFI-R/INS-R Antagonist OSI-906

Introduction: Dysregulation of the mTOR and IGF pathways have been suggested to be involved in the pathogenesis of pheochromocytomas (PCC). mTOR inhibitors, such as sirolimus (S) and everolimus (E), as well as IGFI-R antagonists such as OSI-906, could be new a treatment for malignant PPC.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: De Martino M

Authors: De Martino M, Feelders R, Dogan F, Van Koetsveld P, De Krijger R,

Keywords: IGF, mTOR, everolimus, OSI-906, pheochromocytoma, PC12, adrenal, neuroendocrine, tumor,

#670 The Relationship Between the Ki-67 Protein and IGF-Related Genes in Gastroenteropancreatic Neuroendocrine Tumor Patients with Normal and Elevated Serum Chromogranin-A

Introduction: GEP-NETs are rare, heterogeneous neoplasms with a distinct biological and clinical behavior. Both IGF-system and Ki-67 indices have been reported as important stimulating factors in carcinogenesis and/or tumor progression. The tumor marker CgA is an independent predictor for survival as well. Currently no data are available about a possible interaction between IGF-system (IGF(-R)s, IRs, BPs) and Ki-67 protein in GEP-NET patients with normal and elevated serum CgA.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: van Adrichem R

Authors: Van Adrichem R, De Herder W, Feelders R, De Martino C, De Krijger R,

Keywords: GEP-NET,

#665 Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate

Introduction: Surgery is the only potential for cure in patients with pancreatic neuroendocrine tumors (pNETs).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Van Vliet E, Van Eijck C, De Krijger R, Nieveen van Dijkum E, Teunissen J,

Keywords: pancreatic net, PRRT, neoadjuvant treatment, survival,